<?xml version='1.0' encoding='utf-8'?>
<document id="28345929"><sentence text="Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions." /><sentence text="Species differences in the expression, activity, regulation, and substrate specificity of metabolizing enzymes preclude the use of animal models to predict clinical drug-drug interactions (DDIs)" /><sentence text=" The objective of this work is to determine if the transgenic (Tg) Cyp3a-/-Tg-3A4Hep/Int and Nr1i2/Nr1i3-/--Cyp3a-/-Tg-PXR-CAR-3A4/3A7Hep/Int (PXR-CAR-CYP3A4/3A7) mouse models could be used to predict in vivo DDI of 10 drugs; alprazolam, bosutinib, crizotinib, dasatinib, gefitinib, ibrutinib, regorafenib, sorafenib, triazolam, and vandetinib (as victims); with varying magnitudes of reported CYP3A4 clinical DDI"><entity charOffset="226-236" id="DDI-PubMed.28345929.s3.e0" text="alprazolam" /><entity charOffset="238-247" id="DDI-PubMed.28345929.s3.e1" text="bosutinib" /><entity charOffset="249-259" id="DDI-PubMed.28345929.s3.e2" text="crizotinib" /><entity charOffset="261-270" id="DDI-PubMed.28345929.s3.e3" text="dasatinib" /><entity charOffset="272-281" id="DDI-PubMed.28345929.s3.e4" text="gefitinib" /><entity charOffset="283-292" id="DDI-PubMed.28345929.s3.e5" text="ibrutinib" /><entity charOffset="294-305" id="DDI-PubMed.28345929.s3.e6" text="regorafenib" /><entity charOffset="307-316" id="DDI-PubMed.28345929.s3.e7" text="sorafenib" /><entity charOffset="318-327" id="DDI-PubMed.28345929.s3.e8" text="triazolam" /><entity charOffset="333-343" id="DDI-PubMed.28345929.s3.e9" text="vandetinib" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e0" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e1" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e2" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e3" e2="DDI-PubMed.28345929.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e3" e2="DDI-PubMed.28345929.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e3" e2="DDI-PubMed.28345929.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e3" e2="DDI-PubMed.28345929.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e3" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e3" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e3" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e4" e2="DDI-PubMed.28345929.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e4" e2="DDI-PubMed.28345929.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e4" e2="DDI-PubMed.28345929.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e4" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e4" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e4" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e5" e2="DDI-PubMed.28345929.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e5" e2="DDI-PubMed.28345929.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e5" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e5" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e5" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e6" e2="DDI-PubMed.28345929.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e6" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e6" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e6" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e7" e2="DDI-PubMed.28345929.s3.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e7" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e7" e2="DDI-PubMed.28345929.s3.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e8" e2="DDI-PubMed.28345929.s3.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s3.e8" e2="DDI-PubMed.28345929.s3.e9" /></sentence><sentence text=" As an assessment of the effect of CYP3A4 inhibition, these drugs were coadministered to Cyp3a-/-Tg-3A4Hep/Int mice with the CYP3A inhibitor, itraconazole"><entity charOffset="142-154" id="DDI-PubMed.28345929.s4.e0" text="itraconazole" /></sentence><sentence text=" For crizotinib, regorafenib, sorafenib, and vandetanib, there was no significant increase of AUC observed; with alprazolam, bosutinib, ibrutinib, dasatinib, and triazolam, pretreatment with itraconazole resulted in a 2-, 4-, 17-, 7-, and 15-fold increase in AUC, respectively"><entity charOffset="5-15" id="DDI-PubMed.28345929.s5.e0" text="crizotinib" /><entity charOffset="17-28" id="DDI-PubMed.28345929.s5.e1" text="regorafenib" /><entity charOffset="30-39" id="DDI-PubMed.28345929.s5.e2" text="sorafenib" /><entity charOffset="45-55" id="DDI-PubMed.28345929.s5.e3" text="vandetanib" /><entity charOffset="113-123" id="DDI-PubMed.28345929.s5.e4" text="alprazolam" /><entity charOffset="125-134" id="DDI-PubMed.28345929.s5.e5" text="bosutinib" /><entity charOffset="136-145" id="DDI-PubMed.28345929.s5.e6" text="ibrutinib" /><entity charOffset="147-156" id="DDI-PubMed.28345929.s5.e7" text="dasatinib" /><entity charOffset="162-171" id="DDI-PubMed.28345929.s5.e8" text="triazolam" /><entity charOffset="191-203" id="DDI-PubMed.28345929.s5.e9" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e0" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e1" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e2" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e3" e2="DDI-PubMed.28345929.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e3" e2="DDI-PubMed.28345929.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e3" e2="DDI-PubMed.28345929.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e3" e2="DDI-PubMed.28345929.s5.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e3" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e3" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e3" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e4" e2="DDI-PubMed.28345929.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e4" e2="DDI-PubMed.28345929.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e4" e2="DDI-PubMed.28345929.s5.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e4" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e4" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e4" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e5" e2="DDI-PubMed.28345929.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e5" e2="DDI-PubMed.28345929.s5.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e5" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e5" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e5" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e6" e2="DDI-PubMed.28345929.s5.e6" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e6" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e6" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e6" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e7" e2="DDI-PubMed.28345929.s5.e7" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e7" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e7" e2="DDI-PubMed.28345929.s5.e9" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e8" e2="DDI-PubMed.28345929.s5.e8" /><pair ddi="false" e1="DDI-PubMed.28345929.s5.e8" e2="DDI-PubMed.28345929.s5.e9" /></sentence><sentence text=" With the exception of gefinitib for which the DDI effect was overpredicted (12-fold in Tg-mice vs 2-fold in the clinic), the magnitude of AUC increase observed in this study was consistent (within 2-fold) with the clinical DDI observed following administration with itraconazole/ketoconazole"><entity charOffset="23-32" id="DDI-PubMed.28345929.s6.e0" text="gefinitib" /><entity charOffset="267-279" id="DDI-PubMed.28345929.s6.e1" text="itraconazole" /><entity charOffset="280-292" id="DDI-PubMed.28345929.s6.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.28345929.s6.e0" e2="DDI-PubMed.28345929.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28345929.s6.e0" e2="DDI-PubMed.28345929.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s6.e0" e2="DDI-PubMed.28345929.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s6.e1" e2="DDI-PubMed.28345929.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s6.e1" e2="DDI-PubMed.28345929.s6.e2" /></sentence><sentence text=" As an assessment of CYP3A4 induction, following rifampin pretreatment to PXR-CAR-3A4/3A7Hep/Int mice, an 8% decrease in vandetanib mean AUC was observed; 39-52% reduction in AUC were observed for dasatinib, ibrutinib, regorafenib, and sorafenib compared to vehicle treated mice"><entity charOffset="49-57" id="DDI-PubMed.28345929.s7.e0" text="rifampin" /><entity charOffset="197-206" id="DDI-PubMed.28345929.s7.e1" text="dasatinib" /><entity charOffset="208-217" id="DDI-PubMed.28345929.s7.e2" text="ibrutinib" /><entity charOffset="219-230" id="DDI-PubMed.28345929.s7.e3" text="regorafenib" /><entity charOffset="236-245" id="DDI-PubMed.28345929.s7.e4" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e0" e2="DDI-PubMed.28345929.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e0" e2="DDI-PubMed.28345929.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e0" e2="DDI-PubMed.28345929.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e0" e2="DDI-PubMed.28345929.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e0" e2="DDI-PubMed.28345929.s7.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e1" e2="DDI-PubMed.28345929.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e1" e2="DDI-PubMed.28345929.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e1" e2="DDI-PubMed.28345929.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e1" e2="DDI-PubMed.28345929.s7.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e2" e2="DDI-PubMed.28345929.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e2" e2="DDI-PubMed.28345929.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e2" e2="DDI-PubMed.28345929.s7.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e3" e2="DDI-PubMed.28345929.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s7.e3" e2="DDI-PubMed.28345929.s7.e4" /></sentence><sentence text=" The greatest effect of rifampin induction was observed with alprazolam, bosutinib, crizotinib, gefitinib, and triazolam where 72-91% decrease in AUC were observed"><entity charOffset="24-32" id="DDI-PubMed.28345929.s8.e0" text="rifampin" /><entity charOffset="61-71" id="DDI-PubMed.28345929.s8.e1" text="alprazolam" /><entity charOffset="73-82" id="DDI-PubMed.28345929.s8.e2" text="bosutinib" /><entity charOffset="84-94" id="DDI-PubMed.28345929.s8.e3" text="crizotinib" /><entity charOffset="96-105" id="DDI-PubMed.28345929.s8.e4" text="gefitinib" /><entity charOffset="111-120" id="DDI-PubMed.28345929.s8.e5" text="triazolam" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e0" e2="DDI-PubMed.28345929.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e0" e2="DDI-PubMed.28345929.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e0" e2="DDI-PubMed.28345929.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e0" e2="DDI-PubMed.28345929.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e0" e2="DDI-PubMed.28345929.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e0" e2="DDI-PubMed.28345929.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e1" e2="DDI-PubMed.28345929.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e1" e2="DDI-PubMed.28345929.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e1" e2="DDI-PubMed.28345929.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e1" e2="DDI-PubMed.28345929.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e1" e2="DDI-PubMed.28345929.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e2" e2="DDI-PubMed.28345929.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e2" e2="DDI-PubMed.28345929.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e2" e2="DDI-PubMed.28345929.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e2" e2="DDI-PubMed.28345929.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e3" e2="DDI-PubMed.28345929.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e3" e2="DDI-PubMed.28345929.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e3" e2="DDI-PubMed.28345929.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e4" e2="DDI-PubMed.28345929.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345929.s8.e4" e2="DDI-PubMed.28345929.s8.e5" /></sentence><sentence text=" With the exception of vandetanib for which rifampin induction was under-predicted, the magnitude of induction observed in this study was consistent (within 2-fold) with clinical observations"><entity charOffset="23-33" id="DDI-PubMed.28345929.s9.e0" text="vandetanib" /><entity charOffset="44-52" id="DDI-PubMed.28345929.s9.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28345929.s9.e0" e2="DDI-PubMed.28345929.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28345929.s9.e0" e2="DDI-PubMed.28345929.s9.e1" /></sentence><sentence text=" These data sets suggest that, with two exceptions, these transgenic mice models were able to exclude or capture the magnitude of CYP3A4 clinical inhibition and induction" /><sentence text=" Data generated in transgenic mice may be used to gain confidence and complement in vitro and in silico methods for assessing DDI potential/liability" /><sentence text="" /></document>